文献速递心境障碍

锂盐与丙戊酸盐治疗期间双相障碍患者的自杀行为:5万例患者8年前瞻性个体内研究

Suicidal Behavior During Lithium and Valproate Treatment: A Within-Individual 8-Year Prospective Study of 50,000 Patients With Bipolar Disorder.
PubMed 文献 · Am J Psychiatry · 2017-06-09

该研究基于瑞典全国登记数据,对51,535例双相障碍患者从2005年至2013年进行个体内设计随访,评估锂盐与丙戊酸盐治疗期间自杀相关事件风险。结果显示锂盐治疗期间自杀相关事件发生率显著降低14%(HR 0.86,95%CI 0.78-0.95),而丙戊酸盐治疗期间无显著降低(HR 1.02,95%CI 0.89-1.15),两者风险比差异有统计学意义;若全程服用锂盐,12%(95%CI 4%-20%)的自杀相关事件或可避免。

要点

  • 锂盐治疗与双相障碍患者自杀相关事件风险降低14%显著相关。
  • 丙戊酸盐治疗未显示与自杀相关事件风险降低的显著关联。
  • 锂盐与丙戊酸盐对自杀相关事件的风险比差异具有统计学意义。

核心结论

  • 锂盐治疗期间双相障碍患者自杀相关事件发生率显著降低,而丙戊酸盐治疗期间无显著降低。
  • 锂盐与丙戊酸盐对自杀相关事件的风险比差异具有统计学意义。
  • 若患者在全部随访期间服用锂盐,12%(95%CI 4%-20%)的自杀相关事件或可避免。
  • 结果提示对于有自杀意图的双相障碍患者应考虑锂盐,但自杀风险仅为临床考量之一。

研究设计与样本

  • 基于瑞典多个全国登记系统的登记链接纵向队列研究,采用个体内设计。
  • 纳入51,535例双相障碍患者,从2005年至2013年随访锂盐和丙戊酸盐治疗情况。
  • 采用分层Cox回归估计治疗期间与未治疗期间自杀相关事件的风险比。
  • 对药物与自杀相关事件的显著关联估计人群归因分数以评估公共卫生影响。

主要发现

  • 随访期间共发生10,648例自杀相关事件。
  • 锂盐治疗期间自杀相关事件发生率降低14%(HR 0.86,95%CI 0.78-0.95)。
  • 丙戊酸盐治疗期间自杀相关事件风险无显著降低(HR 1.02,95%CI 0.89-1.15)。
  • 锂盐与丙戊酸盐对自杀相关事件的风险比差异有统计学意义。
  • 人群归因分数估计显示12%(95%CI 4%-20%)的自杀相关事件若全程服用锂盐或可避免。

关键数值与推荐

  • 锂盐治疗期间自杀相关事件HR 0.86(95%CI 0.78-0.95),发生率降低14%。
  • 丙戊酸盐治疗期间自杀相关事件HR 1.02(95%CI 0.89-1.15),无显著关联。
  • 锂盐与丙戊酸盐风险比差异有统计学意义。
  • 人群归因分数12%(95%CI 4%-20%),对应全程锂盐可避免的自杀相关事件比例。

临床怎么用

  • 对于有自杀意图的双相障碍患者,临床应考虑使用锂盐。
  • 丙戊酸盐未显示对自杀相关事件的保护关联,选择药物时需结合自杀风险考量。
  • 自杀风险仅为临床决策的考量因素之一,需综合评估后个体化用药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Conclusions regarding lithium's antisuicidal effect for bipolar disorder have been limited due to nonrepresentative subjects and potential confounding factors, including varying severity of illness. Findings regarding the effect of valproate, the most common alternative to lithium, are inconsistent for suicidal behavior. This study investigated the associations of these two drugs with the risk of suicide-related events, and possible differences between drugs, by using within-individual designs in a register-based longitudinal cohort. METHOD: Through linkage of multiple Swedish national registers, 51,535 individuals with bipolar disorder were followed from 2005 to 2013 for treatment with lithium and valproate. Stratified Cox regression was used to estimate the hazard ratios of suicide-related events during treated periods compared with untreated periods. For significant associations between medication and suicide-related events, the population attributable fraction was estimated to assess the public health impact for patients with bipolar disorder. RESULTS: During follow-up, 10,648 suicide-related events occurred. The incidence rate was significantly decreased by 14% during lithium treatment (hazard ratio 0.86, 95% confidence interval [CI] 0.78-0.95) but not during valproate treatment (hazard ratio 1.02, 95% CI 0.89-1.15). The difference in hazard ratios of suicide-related events between lithium and valproate was statistically significant. Estimates of the population attributable fraction suggested that 12% (95% CI 4%-20%) of suicide-related events could have been avoided if patients had taken lithium during the entire follow-up. CONCLUSIONS: The results suggest that lithium should be considered for patients with bipolar disorder with suspected suicidal intentions, although risk for suicide is only one of the considerations when providing clinical care.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Song J, Sjölander A, Joas E, et al. Suicidal Behavior During Lithium and Valproate Treatment: A Within-Individual 8-Year Prospective Study of 50,000 Patients With Bipolar Disorder. Am J Psychiatry. 2017. PMID: 28595491. doi:10.1176/appi.ajp.2017.16050542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。